Spherox

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
22-08-2023
产品特点 产品特点 (SPC)
22-08-2023
公众评估报告 公众评估报告 (PAR)
14-07-2021

有效成分:

spheroids of human autologous matrix-associated chondrocytes

可用日期:

CO.DON Gmbh

ATC代码:

M09AX02

INN(国际名称):

spheroids of human autologous matrix-associated chondrocytes

治疗组:

Other drugs for disorders of the musculo-skeletal system

治疗领域:

Cartilage Diseases

疗效迹象:

Repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee (International Cartilage Repair Society [ICRS] grade III or IV) with defect sizes up to 10 cm2 in adults.,

產品總結:

Revision: 8

授权状态:

Authorised

授权日期:

2017-07-10

资料单张

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SPHEROX 10-70 SPHEROIDS/CM
2 IMPLANTATION SUSPENSION
spheroids of human autologous matrix-associated chondrocytes
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN WITH THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor.
•
If you get any side effects, talk to your doctor or physical
therapist. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Spherox is and what it is used for
2.
What you need to know before you are given Spherox
3.
How to use Spherox
4.
Possible side effects
5.
How to store Spherox
6.
Contents of the pack and other information
1.
WHAT SPHEROX IS AND WHAT IT IS USED FOR
Spherox is a medicine used to
REPAIR DAMAGE TO THE CARTILAGE OF THE KNEE
in adults and in
adolescents whose bones in the joint have finished growing. Cartilage
is a hard smooth layer inside
your joints, on the ends of the bones. It protects the bones and
allows joints to work smoothly.
Spherox is used in adults, or adolescents whose bones have finished
growing, when the cartilage in the
knee joint is damaged, for example by acute injury, such as a fall or
long-term wear due to incorrect
weight bearing on the joint. Spherox is used to treat defects up to 10
cm² in size.
Spherox consists of so-called spheroids. A spheroid looks like a tiny
pearl made of cartilage cells and
cartilage material derived from your own body. To make the spheroids,
a small cartilage sample is
taken from one of your joints during a minor operation, and then grown
in the laboratory to make the
medicine. The spheroids are implanted by surgery to the damaged
cartilage area and stick to the
damaged part. They are then expected to repair the damage with healthy
and functional cartilage over
time.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN SPHEROX
DO NOT USE SPHEROX IF
•
the bones in the knee joi
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Spherox 10-70 spheroids/cm
2
implantation suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1
GENERAL DESCRIPTION
Spheroids of human autologous matrix-associated chondrocytes for
implantation suspended in isotonic
sodium chloride solution.
2.2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Spheroids are spherical aggregates of
_ex vivo_
expanded human autologous chondrocytes and self-
synthesized extracellular matrix.
Each pre-filled syringe or applicator contains a specific number of
spheroids according to the defect
size (10-70 spheroids/cm
2
) to be treated.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Implantation suspension.
White to yellowish spheroids of matrix-associated autologous
chondrocytes in a clear, colourless
solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Repair of symptomatic articular cartilage defects of the femoral
condyle and the patella of the knee
(International Cartilage Regeneration & Joint Preservation Society
[ICRS] grade III or IV) with defect
sizes up to 10 cm
2
in adults and adolescents with closed epiphyseal growth plate in the
affected joint.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Spherox is intended for autologous use only. It must be administered
by a specialised orthopedic
surgeon and in a medical facility.
Posology
10-70 spheroids are applied per square centimetre defect.
_Elderly _
The safety and efficacy of Spherox in patients aged over 50 years have
not been established. No data
are available.
_Paediatric population _
The safety and efficacy of Spherox in children and adolescents with
still open epiphyseal growth plate
in the affected joint have not been established. No data are
available.
3
Method of administration
For intraarticular use.
Spherox is administered to patients by intraarticular implantation.
The treatment with Spherox is a two-step procedure.
In a first step, a biopsy must be performed during a surgical
procedure (preferably an arthros
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 22-08-2023
产品特点 产品特点 保加利亚文 22-08-2023
公众评估报告 公众评估报告 保加利亚文 14-07-2021
资料单张 资料单张 西班牙文 22-08-2023
产品特点 产品特点 西班牙文 22-08-2023
公众评估报告 公众评估报告 西班牙文 14-07-2021
资料单张 资料单张 捷克文 22-08-2023
产品特点 产品特点 捷克文 22-08-2023
公众评估报告 公众评估报告 捷克文 14-07-2021
资料单张 资料单张 丹麦文 22-08-2023
产品特点 产品特点 丹麦文 22-08-2023
公众评估报告 公众评估报告 丹麦文 14-07-2021
资料单张 资料单张 德文 22-08-2023
产品特点 产品特点 德文 22-08-2023
公众评估报告 公众评估报告 德文 14-07-2021
资料单张 资料单张 爱沙尼亚文 22-08-2023
产品特点 产品特点 爱沙尼亚文 22-08-2023
公众评估报告 公众评估报告 爱沙尼亚文 14-07-2021
资料单张 资料单张 希腊文 22-08-2023
产品特点 产品特点 希腊文 22-08-2023
公众评估报告 公众评估报告 希腊文 14-07-2021
资料单张 资料单张 法文 22-08-2023
产品特点 产品特点 法文 22-08-2023
公众评估报告 公众评估报告 法文 14-07-2021
资料单张 资料单张 意大利文 22-08-2023
产品特点 产品特点 意大利文 22-08-2023
公众评估报告 公众评估报告 意大利文 14-07-2021
资料单张 资料单张 拉脱维亚文 22-08-2023
产品特点 产品特点 拉脱维亚文 22-08-2023
公众评估报告 公众评估报告 拉脱维亚文 14-07-2021
资料单张 资料单张 立陶宛文 22-08-2023
产品特点 产品特点 立陶宛文 22-08-2023
公众评估报告 公众评估报告 立陶宛文 14-07-2021
资料单张 资料单张 匈牙利文 22-08-2023
产品特点 产品特点 匈牙利文 22-08-2023
公众评估报告 公众评估报告 匈牙利文 14-07-2021
资料单张 资料单张 马耳他文 22-08-2023
产品特点 产品特点 马耳他文 22-08-2023
公众评估报告 公众评估报告 马耳他文 14-07-2021
资料单张 资料单张 荷兰文 22-08-2023
产品特点 产品特点 荷兰文 22-08-2023
公众评估报告 公众评估报告 荷兰文 14-07-2021
资料单张 资料单张 波兰文 22-08-2023
产品特点 产品特点 波兰文 22-08-2023
公众评估报告 公众评估报告 波兰文 14-07-2021
资料单张 资料单张 葡萄牙文 22-08-2023
产品特点 产品特点 葡萄牙文 22-08-2023
公众评估报告 公众评估报告 葡萄牙文 14-07-2021
资料单张 资料单张 罗马尼亚文 22-08-2023
产品特点 产品特点 罗马尼亚文 22-08-2023
公众评估报告 公众评估报告 罗马尼亚文 14-07-2021
资料单张 资料单张 斯洛伐克文 22-08-2023
产品特点 产品特点 斯洛伐克文 22-08-2023
公众评估报告 公众评估报告 斯洛伐克文 14-07-2021
资料单张 资料单张 斯洛文尼亚文 22-08-2023
产品特点 产品特点 斯洛文尼亚文 22-08-2023
公众评估报告 公众评估报告 斯洛文尼亚文 14-07-2021
资料单张 资料单张 芬兰文 22-08-2023
产品特点 产品特点 芬兰文 22-08-2023
公众评估报告 公众评估报告 芬兰文 14-07-2021
资料单张 资料单张 瑞典文 22-08-2023
产品特点 产品特点 瑞典文 22-08-2023
公众评估报告 公众评估报告 瑞典文 14-07-2021
资料单张 资料单张 挪威文 22-08-2023
产品特点 产品特点 挪威文 22-08-2023
资料单张 资料单张 冰岛文 22-08-2023
产品特点 产品特点 冰岛文 22-08-2023
资料单张 资料单张 克罗地亚文 22-08-2023
产品特点 产品特点 克罗地亚文 22-08-2023
公众评估报告 公众评估报告 克罗地亚文 14-07-2021

查看文件历史